News Briefs

The FDA approved an additional indication for Jardiance (empagliflozin), allowing the drug to be used to “reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF),” according to a press release from Boehringer Ingelheim and Eli Lilly and Co. According to an Aug. 18 press release, the drug was already approved to “lower blood sugar along with diet and exercise in adults with type 2 diabetes, reduce the risk of cardiovascular death in adults with type 2 diabetes who also have known cardiovascular disease, [and] reduce the risk of cardiovascular death and hospitalization for heart failure…in adults with heart failure.”

© 2023 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

doctor-speaking-to-a-patient
May 25

Commercial Insurance Restrictions Complicate Biosimilar Adoption

READ MORE
shell-game
May 25

‘Shell Game’ or Rebate Maximizers? FTC Probe Reignites Debate Over GPOs

Read More
pills-in-hand
May 25

As Weight Loss Drugs’ Star Rises, Plan Sponsors, Researchers Worry About Costs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today